Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

August 31, 2026

Conditions
HIV Prevention
Interventions
DRUG

TLD - Tenofovir Disoproxil Fumarate / Lamivudine / Dolutegravir

Dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets, a combination of dolutegravir (integrase strand transfer inhibitor \[INSTI\]), lamivudine, and tenofovir disoproxil fumarate (both nucleoside reverse transcriptase inhibitors), is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg

Trial Locations (3)

2193

Ezintsha, a division of Wits Health Consortium, Johannesburg

3935

Africa Health Research Institute (AHRI), Durban

7925

Desmond Tutu Health Foundation, Cape Town

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

University of Witwatersrand, South Africa

OTHER

NCT06485154 - Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial | Biotech Hunter | Biotech Hunter